We would love to hear your thoughts about our site and services, please take our survey here.
rocquet,
Are you here to deramp and promote AVCT & ODX?
If you are not interested in this BRH share, advise to leave this BB.
I have posted earlier of the deficiencies of AVCT, and furthermore, both the LFT tests can’t determine asymptomatic and pre-symptomatic people.
bbrq648
Patience will prevail.
Buying Opportunity.
Buy what you can afford and leave the BRH shares for long term investment.
Quick sellers will regret for selling too early for few pennies whereas pound sterling profits to be made.
Don’t fall prey for deramper and DYOR, buy and hold till the product(s) come to the market or otherwise.
mathsprof,
All investors do their own research prior to investing in a share.
We are fully aware of the CEO and associated details of BRH.
BRH have several good investment in upcoming medical research and their equipment manufactured with existing manufacturers of D100 and upgrading to D200 and other developments associated with COVID-19, Sepsis, Alzheimer’s and bladder testing and assessment of future viruses using the development tests of COVID-19 will be help Fast track solutions for the future eradication of new viruses.
Thus, this BRH will be a long term investment and not suitable for traders and investors who wants to make quick bucks.
I had a brief chat on 07-Mar-2021 morning with Mr Vivian D Hallam ( COO - BRH), and had raised several questions - responses are given below for all genuine investors:
1) Test results ambiguity - Test progressing to extend the clinical validation testing to improve more accuracy;
2) CE & UKCA certification - Will be carried out after having at least further 250 tests;
3) Why the RNS was not clear in stating the viral counts of variation up to 10000 / ml? - Confirmation that the test accuracy of BRH/ Paraytec as specified in 01-Mar-2021 & 26-Mar-2021;
4) When will the AGM be held - This will be notified to all investors after preparing the annual accounts;
5) Why CEO selling shares at a critical juncture - VH could not answerable to CEO ( no comments);
6) Why no dates mentioned for the next RNS? - BRH/ Paraytec could not estimate a proper time line during Clinical Validation by PHA & their support team;
7) Why marketing was not done? - BRH/ Paraytec are in the process of getting this commenced soon.
Finally, VH had confirmed confidence in the test, accuracy and suitable to identify suitable COVID-19 variants, which is not possible by any LFTs.
WHO revised SARS-Cov-2 as airborne transmission viruses, and thus identifying asymptomatic and pre-symptomatic cases and isolation the people to stop the spread.
Hence all genuine investors - make use of this buying opportunity and invest for long term, and details of other sisters companies progresses will be soon forthcoming.
bbrq648
Prof. Carl Smythe wrote in the Twitter as follows:
1. Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.
This means that our BRH test can identify low viral loads, which would be found in asymptomatics and pre-symptomatic people.
Notes:
a) It is obviously easy to identify symptomatic people whom will have high viral loads.
b) To stop spreading of the viruses, it is important to identify asymptomatics and pre-symptomatic people and isolate them.
c) This work was not only important and procedurally adopted by BRH.
d) The issue of LFT Test Sensitivity was identified and rectified in BRH test by clearly identifying false positives and false negatives cases, and minimising and increasingly the accuracy of BRH tests.
A small hints were given in BRH RNS dated 01 & 26-Mar-2021, but was not captured by several investors and media, and traders and institutional investors. Read also the latest RNS, where Testing will be with various ranges of virons.
Hold on to this shares and avoid selling prematurely without knowing the full capabilities of BRH testing.
Hope this will give some insight for holding or buying shares in BRH/ Paraytec.
Paraytec is 100% owned by BRH, and are in the current Clinical Validation, and development headed by Prof Carl Smythe and his University of Sheffield Team.
Calm before Storm.
Keep invested and reap your harvest handsomely.
Excepts taken from LANCET MEDICAL JOURNAL is given below:
Third, asymptomatic or presymptomatic transmission of SARS-CoV-2 from people who are not coughing or sneezing is likely to account for at least a third, and perhaps up to 59%, of all transmission globally and is a key way SARS-CoV-2 has spread around the world,8 supportive of a predominantly airborne mode of transmission. Direct measurements show that speaking produces thousands of aerosol particles and few large droplets,9 which supports the airborne route.
Full article path is attached here for reference.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00869-2/fulltext
This is what BRH/ Paraytec Test is all about identify and isolate asymptomatic and pre-symptomatic people to stop spreading airborne transmissions.
bbrq648
Posters here have and are showing their true colours in this BB for the last three days and today.
Best of Luck to all Genuine shareholders.
It is a great value and opportunity to buy this Share at this price, and hold for long term gains.
bbrq648
parolee,
You posted as buys at 75p earlier ( one of your five BRH posts)
Why did you buy if you presumed that there will be sellers including BOD members?
No point of postulating about CEO sale. If sos there will be a TR1.
So don’t post on assumptions.